Find Clinical Trial

Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder. A 6-week randomised, double-blind parallel groups study versus comparator, followed by a double-blind optional treatment extension period up to 6 months.


← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

Active substance/
Medical device

S020098, AGOMELATINE

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS020098
Protocol CodeCL3-20098-056
EudraCT Code2006-004716-48
ISRCTN CodeISRCTN44737909


Documents and links

Results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility